IDP-Pharma
Pipeline
MYC / IDP-121 (Oncology)
| Discovery | IND Enabling | Clinical |
MYC is a transcription factor crucial for cell growth and proliferation, dysregulated in >50% of cancers. Its overexpression is linked to aggressive tumor behaviour and poor patient prognosis.
Through our proprietary technology platform, we developed IDP-121, a novel inhibitor targeting MYC, currently in clinical Phase I for haematological malignancies and with potential applications across various cancer types.
HIF-1 and HIF-2 / IDP-601 (Oncology)
| Discovery | IND Enabling | Clinical |
Hypoxia Inducible Factor (HIF) serves as a regulatory complex facilitating cellular adaptation to oxygen deprivation, particularly notable within the hypoxic microenvironment of solid tumours. The upregulation of both HIF-1 and HIF-2 in most solid tumours is frequently associated with unfavourable clinical prognoses.
Through the INTRAMETICS platform, we developed IDP-601, a pioneering dual inhibitor of HIF-1 and HIF-2. IDP-601 is currently undergoing IND enabling studies, showing significant promise for enhancing therapeutic outcomes in hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and various other solid tumour types, surpassing HIF-2 selective inhibitors in development.
ASCL1 / IDP-233 (Oncology)
| Discovery | IND Enabling | Clinical |
ASCL1 is a transcription factor pivotal for neural development and frequently implicated in neuroendocrine tumours. Its aberrant expression is associated with tumour progression and adverse clinical outcomes.
Leveraging our cutting-edge technology platform, we have developed a novel inhibitor specifically targeting ASCL1, offering potential therapeutic benefits across diverse neuroendocrine malignancies (SCLC, nePC).
Our pioneering ASCL1 inhibitor IDP-233, is currently undergoing toxicology studies and represents a significant leap forward in cancer therapy, addressing a critical need for targeted interventions.
MIFT (Dermatology, Licensed)
| Discovery | IND Enabling | Clinical |
MIFT, a transcriptional regulator prevalent in dermatology, plays a key role in skin homeostasis and pathology. Dysregulation of MIFT is often associated with various dermatological conditions, including melanoma, making it a promising therapeutic target.
Expanding beyond oncology, our company leveraged its platform to develop novel MIFT inhibitors through licensing agreements. These advancements hold potential for revolutionizing dermatological treatments and are currently in phase I clinical trial showing positive outcomes.
Undisclosed (Partnered with Pharma)
| Discovery | IND Enabling | Clinical |
Respiratory, Ophthalmology
